Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options
If you are a long-term stockholder in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) --
What’s Happening:
- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of long-term stockholders following a class action complaint that was filed against Unicycive on August 15, 2025 with a Class Period from March 29, 2024 to June 27, 2025. Our investigation concerns whether the board of directors of Unicycive have breached their fiduciary duties to the company.
Details:
- According to the complaint, defendants touted the prospects of its New Drug Application ("NDA") for oxylanthanum carbonate ("OLC") for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis and assured investors of the Company's readiness and ability to satisfy the U.S. Drug and Food Administration's ("FDA") manufacturing compliance requirements. The complaint further alleges, however, that defendants failed to disclose that Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated.
- On June 10, 2025, Unicycive announced that the FDA "had identified deficiencies in cGMP [current good manufacturing practice] compliance at a third-party manufacturing vendor"—specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")—"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded." On this news, the price of Unicycive's stock fell over 40%. Then, on June 30, 2025, Unicycive announced that the FDA had issued a Complete Response Letter for the OCL NDA, citing the previously identified cGMP deficiencies at the third-party subcontractor of its CDMO. On this news, Unicycive's stock fell almost 30%, to close at $4.77 per share on June 30, 2025.
Next Steps:
- If you are a long-term stockholder of Unicycive, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
